CoChat

The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.

Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study

Open access

Abstract

BACKGROUND: Most neonatal and infantile-onset epilepsies have presumed genetic aetiologies, and early genetic diagnoses have the potential to inform clinical management and improve outcomes. We therefore aimed to determine the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in this population. METHODS: We conducted an international, multicentre, cohort study (Gene-STEPS), which is a pilot study of the International Precision Child Health Partnership (IPCHiP). IPCHiP is a consortium of four paediatric centres with tertiary-level subspecialty services in Australia, Canada, the UK, and the USA. We recruited infants with new-onset epilepsy or complex febrile seizures from IPCHiP centres, who were younger than 12 months at seizure onset. We excluded infants with simple febrile seizures, acute provoked seizures, known acquired cause, or known genetic cause. Blood samples were collected from probands and available biological parents. Clinical data were collected from medical records, treating clinicians, and parents. Trio genome sequencing was done when both parents were available, and duo or singleton genome sequencing was done when one or neither parent was available. Site-specific protocols were used for DNA extraction and library preparation. Rapid genome sequencing and analysis was done at clinically accredited laboratories, and results were returned to families. We analysed summary statistics for cohort demographic and clinical characteristics and the timing, diagnostic yield, and clinical impact of rapid genome sequencing. FINDINGS: Between Sept 1, 2021, and Aug 31, 2022, we enrolled 100 infants with new-onset epilepsy, of whom 41 (41%) were girls and 59 (59%) were boys. Median age of seizure onset was 128 days (IQR 46-192). For 43 (43% [binomial distribution 95% CI 33-53]) of 100 infants, we identified genetic diagnoses, with a median time from seizure onset to rapid genome sequencing result of 37 days (IQR 25-59). Genetic diagnosis was associated with neonatal seizure onset versus infantile seizure onset (14 [74%] of 19 vs 29 [36%] of 81; p=0·0027), referral setting (12 [71%] of 17 for intensive care, 19 [44%] of 43 non-intensive care inpatient, and 12 [28%] of 40 outpatient; p=0·0178), and epilepsy syndrome (13 [87%] of 15 for self-limited epilepsies, 18 [35%] of 51 for developmental and epileptic encephalopathies, 12 [35%] of 34 for other syndromes; p=0·001). Rapid genome sequencing revealed genetic heterogeneity, with 34 unique genes or genomic regions implicated. Genetic diagnoses had immediate clinical utility, informing treatment (24 [56%] of 43), additional evaluation (28 [65%]), prognosis (37 [86%]), and recurrence risk counselling (all cases). INTERPRETATION: Our findings support the feasibility of implementation of rapid genome sequencing in the clinical care of infants with new-onset epilepsy. Longitudinal follow-up is needed to further assess the role of rapid genetic diagnosis in improving clinical, quality-of-life, and economic outcomes. FUNDING: American Academy of Pediatrics, Boston Children's Hospital Children's Rare Disease Cohorts Initiative, Canadian Institutes of Health Research, Epilepsy Canada, Feiga Bresver Academic Foundation, Great Ormond Street Hospital Charity, Medical Research Council, Murdoch Children's Research Institute, National Institute of Child Health and Human Development, National Institute for Health and Care Research Great Ormond Street Hospital Biomedical Research Centre, One8 Foundation, Ontario Brain Institute, Robinson Family Initiative for Transformational Research, The Royal Children's Hospital Foundation, University of Toronto McLaughlin Centre.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1474-4422(23)00246-6

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study profile GS=genome sequencing. *Not via this study.
Figure 1 Study profile GS=genome sequencing. *Not via this study.CC BY · PubMed Central
Figure 2 Rapid GS workflow and summary of genetic diagnoses (A) Rapid GS workflow and time intervals, created with BioRender.com. (B) Genetic diagnoses arranged by age at seizure onset. Each square represents an infant who received a genetic diagnosis. The affected gene or genomic region is denoted in the square. The infant with a diagnostic SCN2A variant and seizure onset in the second month of life classified as self-limited neonatal epilepsy was born prematurely and was younger than 44 weeks postmenstrual age at seizure onset. (C) Types of variants in diagnostic cases. Data are n (%) of 46 total variants. (D) Mode of inheritance of variants in diagnostic cases. Data are n (%) of 43 total diagnoses. GS=genome sequencing. DEE=developmental and epileptic encephalopathy.
Figure 2 Rapid GS workflow and summary of genetic diagnoses (A) Rapid GS workflow and time intervals, created with BioRender.com. (B) Genetic diagnoses arranged by age at seizure onset. Each square represents an infant who received a genetic diagnosis. The affected gene or genomic region is denoted in the square. The infant with a diagnostic SCN2A variant and seizure onset in the second month of life classified as self-limited neonatal epilepsy was born prematurely and was younger than 44 weeks postmenstrual age at seizure onset. (C) Types of variants in diagnostic cases. Data are n (%) of 46 total variants. (D) Mode of inheritance of variants in diagnostic cases. Data are n (%) of 43 total diagnoses. GS=genome sequencing. DEE=developmental and epileptic encephalopathy.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 33 references

Cited by

See all 80

Metadata

Authors
D'Gama, A. M., Mulhern, S., Sheidley, B. R., Boodhoo, F., Buts, S., Chandler, N. J., Cobb, J., Curtis, M., Higginbotham, E. J., Holland, J., Khan, T., Koh, J., Liang, N. S. Y., McRae, L., Nesbitt, S. E., Oby, B. T., Paternoster, B., Patton, A., Rose, G., Scotchman, E., Valentine, R., Wiltrout, K. N., Hayeems, R. Z., Jain, P., Lunke, S., Marshall, C. R., Rockowitz, S., Sebire, N. J., Stark, Z., White, S. M., Chitty, L. S., Cross, J. H., Scheffer, I. E., Chau, V., Costain, G., Poduri, A., Howell, K. B., & McTague, A.
Affiliations
  • Victorian Clinical Genetics Services (AU)
  • Boston Children's Hospital (US)
  • Great Ormond Street Hospital (GB)
  • Universitätsklinikum Aachen (DE)
  • Murdoch Children's Research Institute (AU)
  • Hospital for Sick Children (CA)
  • SickKids Foundation (CA)
  • University of Toronto (CA)
  • Frimley Park Hospital (GB)
  • The University of Melbourne (AU)
  • Royal Children's Hospital (AU)
Corresponding author
McTague, Amy
Venue
The Lancet Neurology
Publisher
Elsevier BV
Published
2023-09
Volume
22
Issue
9
Pages
812-825
ISSN
1474-4422 (ISSN-L)
OpenAlex
W4385889024
Cited by
80
References
33
Citations by year
2026: 19 · 2025: 30 · 2024: 28 · 2023: 3
FWCI
16.22
Type
journal article
Language
en
Update notices
erratum (2023-12-01)
Open access
Licence
Locations
  • The Lancet Neurology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion, cc-by)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
Funders
  • Wellcome Trust
  • National Institute for Health and Care Research
  • Medical Research Council (MR/T007087/1)
  • National Health and Medical Research Council (2006841)
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development (P50HD105351, T32HD098061)
Topics
  • Health Sciences › Medicine › Clinical Neurology › Epilepsy research and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomics and Rare Diseases
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
infantile epilepsy, rapid genome sequencing, neonatal seizures, complex febrile seizures, genetic diagnosis, diagnostic yield, clinical utility
MeSH terms
Child, Seizures, Febrile, Epilepsy, Feasibility Studies, Female, Humans, Infant, Newborn, Male, Ontario, Pilot Projects, Cohort Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study. https://app.cochat.ai/papers/10.1016/s1474-4422(23)00246-6
The paper
D'Gama, A. M., Mulhern, S., Sheidley, B. R., Boodhoo, F., Buts, S., Chandler, N. J., Cobb, J., Curtis, M., Higginbotham, E. J., Holland, J., Khan, T., Koh, J., Liang, N. S. Y., McRae, L., Nesbitt, S. E., Oby, B. T., Paternoster, B., Patton, A., Rose, G., . . . McTague, A. (2023). Evaluation of the feasibility, diagnostic yield, and clinical utility of rapid genome sequencing in infantile epilepsy (Gene-STEPS): an international, multicentre, pilot cohort study. The Lancet Neurology. https://doi.org/10.1016/s1474-4422(23)00246-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.